Next Financial Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Next Financial Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$0	Hold	150	–	–	﹤0.01%	3023
2021 Q3	$1K	Hold	150	–	–	﹤0.01%	2714
2021 Q2	$1K	Sell	150 -385	-72%	-$1.85K	﹤0.01%	2595
2021 Q1	$2K	Sell	535 -1,400	-72%	-$6.35K	﹤0.01%	2351
2020 Q4	$6K	Hold	1,935	–	–	﹤0.01%	1955
2020 Q3	$6K	Buy	+1,935	New	+$7.11K	﹤0.01%	1807
2020 Q2	–	Sell	-1,935	Closed	-$7K	–	2008
2020 Q1	$7K	Sell	1,935 -1,598	-45%	-$7.42K	﹤0.01%	1637
2019 Q4	$21K	Buy	3,533 +1,598	+83%	+$10.9K	﹤0.01%	1520
2019 Q3	$15K	Hold	1,935	–	–	﹤0.01%	1568
2019 Q2	$26K	Buy	1,935 +1,785	+1,190%	+$20.6K	﹤0.01%	1379
2019 Q1	$1K	Sell	150 -2,161	-94%	-$10.5K	﹤0.01%	1601
2018 Q4	$7K	Buy	2,311 +2,161	+1,441%	+$11.8K	﹤0.01%	1467
2018 Q3	$1K	Buy	+150	New	+$1.15K	﹤0.01%	1441
2017 Q4	–	Sell	-650	Closed	-$6K	–	1512
2017 Q3	$6K	Buy	650 +500	+333%	+$5.29K	﹤0.01%	1391
2017 Q2	$3K	Hold	150	–	–	﹤0.01%	1693
2017 Q1	$3K	Buy	+150	New	+$2.98K	﹤0.01%	1649

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Next Financial Group's ZYNE Position: Q4 2021 in Review

Next Financial Group held its Zynerba Pharmaceuticals, Inc (ZYNE) position steady in Q4 2021 at 150 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Next Financial Group first reported a position in ZYNE in Q1 2017 and has held it in 16 quarters since. The position peaked at $26K in Q2 2019. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2021.

Next Financial Group held 150 shares of Zynerba Pharmaceuticals, Inc worth $0 as of Q4 2021.
Next Financial Group left its Zynerba Pharmaceuticals, Inc share count unchanged in Q4 2021.
Zynerba Pharmaceuticals, Inc made up ﹤0.01% of Next Financial Group's portfolio in Q4 2021, its #3023 holding.
Next Financial Group first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and has held it in 16 quarters since.
Next Financial Group's Zynerba Pharmaceuticals, Inc position peaked at $26K in Q2 2019.
62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.